Table 1 Patient characteristics at baseline in Studies I and II
From: Portable NIV for patients with moderate to severe COPD: two randomized crossover trials
Total (N = 61) | Study I* (N = 38) | Study II# (N = 23) | P | |
|---|---|---|---|---|
Age [years] | 67 ± 8 | 66.9 ± 7.4 | 67.6 ± 8.7 | 0.74 |
Female gender [%] | 37.7 | 32 | 47.8 | 0.25 |
FEV1 [%pred] | 30.3 ± 8.9 | 30.3 ± 8 | 29.8 ± 10.4 | 0.99 |
FEV1 [liter] | 0.85 ± 0.26 | 0.88 ± 0.26 | 0.78 ± 0.25 | 0.25 |
FVC [%pred] | 66.25 ± 18.9 | 63.2 ± 19.9 | 70.8 ± 15.7 | 0.13 |
FVC [liter] | 2.37 ± 0.86 | 2.4 ± 0.9 | 2.31 ± 0.81 | 0,67 |
FEV1/FVC ratio [%] | 37 ± 10.4 | 37.5 ± 10.3 | 35.7 ± 10.4 | 0.31 |
TLC [%pred] | 117.6 ± 20.9 | 117.7 ± 18.8 | 117.3 ± 23.9 | 0.94 |
RV [%pred] | 202.5 ± 54.7 | 203.7 ± 49.6 | 200.5 ± 68.5 | 0.84 |
P0.1 [kPa] | 0.48 ± 0.25 | 0.53 ± 0.25 | 0.42 ± 0.14 | 0.25 |
PImax [kPa] | 5.5 ± 22.3 | 5.9 ± 2.3 | 4.9 ± 2 | 0.16 |
PEmax [kPa] | 10.0 ± 3.9 | 9.6 ± 3.7 | 10.7 ± 4.1 | 0.41 |
Nasal sniff [kPa] | 4.8 ± 1.5 | 5.4 ± 1.5 | 4.1 ± 1.6 | 0.01 |
Cumulative smoking dosage [pack years]Υ | 53.1 ± 23.6 | 55.2 ± 23.4 | 49.8 ± 23.4 | 0.32 |
BMI [kg/m2] | 26.6 ± 5.9 | 24.5 ± 3.9 | 30 ± 6.9 | 0.003 |
pH | 7.42 ± 0.03 | 7.42 ± 0.03 | 7.41 ± 0.03 | 0.4 |
PaO2 [mmHg] | 65.8 ± 11.7 | 60.6 ± 6.8 | 74.3 ± 13 | < 0.001 |
PaCO2 [mmHg] | 42.4 ± 6.1 | 41.3 ± 6.9 | 44.4 ± 3.6 | 0.01 |
HCO3− [mmol/l] | 27 ± 2.4 | 26.3 ± 2.2 | 28.2 ± 2.3 | 0.01 |
Supplemental oxygen [% of patients]; [l/min]** | 38.3; 2.6 ± 1.2 | 18.4; 1.9 ± 0.6 | 76; 3 ± 1.3 | < 0.001 |